Enliven Therapeutics, Inc. (ELVN)
ELVN Stock Price Chart
Explore Enliven Therapeutics, Inc. interactive price chart. Choose custom timeframes to analyze ELVN price movements and trends.
ELVN Company Profile
Discover essential business fundamentals and corporate details for Enliven Therapeutics, Inc. (ELVN) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
12 Mar 2020
Employees
62.00
CEO
Richard A. Fair
Description
Enliven Therapeutics, Inc. is a biopharmaceutical enterprise, currently in the clinical development phase, dedicated to discovering and advancing small molecule therapeutic agents aimed at combating cancer. Its pipeline includes ELVN-001, a small molecule kinase inhibitor currently in a Phase 1 clinical trial for adult patients with chronic myeloid leukemia. Another key candidate, ELVN-002, also a small molecule kinase inhibitor, has begun a Phase 1 clinical assessment for individuals with cancers exhibiting an abnormal HER2 gene. The company's base of operations is located in Boulder, Colorado.
ELVN Financial Timeline
Browse a chronological timeline of Enliven Therapeutics, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 12 Aug 2026
EPS estimate is -$0.38.
Earnings released on 7 May 2026
EPS came in at -$0.38 surpassing the estimated -$0.44 by +13.64%.
Earnings released on 3 Mar 2026
EPS came in at -$0.48 falling short of the estimated -$0.42 by -14.29%.
Earnings released on 12 Nov 2025
EPS came in at -$0.32 surpassing the estimated -$0.43 by +25.58%.
Earnings released on 13 Aug 2025
EPS came in at -$0.49 surpassing the estimated -$0.53 by +7.55%.
Earnings released on 14 May 2025
EPS came in at -$0.57 falling short of the estimated -$0.51 by -11.76%.
Earnings released on 13 Mar 2025
EPS came in at -$0.46 surpassing the estimated -$0.53 by +13.21%.
Earnings released on 13 Nov 2024
EPS came in at -$0.48 surpassing the estimated -$0.52 by +7.69%.
Earnings released on 13 Aug 2024
EPS came in at -$0.41 surpassing the estimated -$0.58 by +29.31%.
Earnings released on 14 May 2024
EPS came in at -$0.54 surpassing the estimated -$0.58 by +6.90%.
Earnings released on 14 Mar 2024
EPS came in at -$0.47 surpassing the estimated -$0.56 by +16.07%, while revenue for the quarter reached $440.00k .
Earnings released on 9 Nov 2023
EPS came in at -$0.51 falling short of the estimated -$0.49 by -4.08%.
Earnings released on 10 Aug 2023
EPS came in at -$0.41 falling short of the estimated -$0.40 by -2.50%.
Earnings released on 11 May 2023
EPS came in at -$0.80 falling short of the estimated -$0.67 by -19.40%.
Stock split effective on 24 Feb 2023
Shares were split 1 : 4 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 10 Feb 2023
EPS came in at $1.23 surpassing the estimated -$0.79 by +256.49%.
Earnings released on 25 Oct 2022
EPS came in at -$0.72 surpassing the estimated -$1.00 by +28.00%.
Earnings released on 3 Aug 2022
EPS came in at -$1.76 surpassing the estimated -$2.05 by +14.15%.
Earnings released on 6 May 2022
EPS came in at -$2.24 surpassing the estimated -$2.31 by +3.03%.
Earnings released on 15 Mar 2022
EPS came in at -$2.12 surpassing the estimated -$3.00 by +29.33%.
Earnings released on 9 Nov 2021
EPS came in at -$2.20 surpassing the estimated -$3.38 by +34.91%.
Earnings released on 6 Aug 2021
EPS came in at -$2.96 surpassing the estimated -$3.20 by +7.50%.
ELVN Stock Performance
Access detailed ELVN performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
